PDS Biotechnology
Develops investigational immunotherapies for cancer and infectious diseases.
Something off on this page? Send us feedback.
Profile
Develops investigational molecularly targeted immunotherapies through the Versamune, PDS01ADC-combination, and Infectimune platforms. The single-segment company’s lead oncology programs include PDS0101/Versamune HPV and PDS01ADC.
Develops proprietary molecularly targeted immunotherapies through the Versamune, PDS01ADC-combination, and Infectimune platforms. Its clinical-stage portfolio includes PDS0101/Versamune HPV, PDS01ADC, and PDS0103/Versamune MUC1 in oncology, with Infectimune for infectious diseases. PDS0101 is the lead program and is in a Phase 3 pembrolizumab-combination trial for HPV16-positive recurrent/metastatic head-and-neck cancer. All cited programs remain investigational.
Operating as one centrally managed reportable segment from Princeton, New Jersey, the company is led by Frank Bedu-Addo. Its work includes clinical development and research collaborations; trial execution, financing, intellectual-property protection, and continued Nasdaq compliance shape the business.
Company facts
Key statistics
Year to date −74.8% · Average volume (30d) 2.0M
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.13 | −$0.18 | −38.5% | — | — | — | −3.64% |
| May 13, 2026Q1 FY26 | −$0.15 | −$0.13 | +13.3% | — | — | — | +7.52% |
| Mar 30, 2026Q4 FY25 | −$0.20 | −$0.14 | +30.0% | — | — | — | +12.77% |
| Nov 13, 2025Q3 FY25 | −$0.21 | −$0.19 | +9.5% | — | — | — | −0.53% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$9.1M | −$7.6M | −$8.1M | −$6.7M | −$6.5M | −$6.5M | |
| Net income | −$8.5M | −$9.4M | −$9.0M | −$7.6M | −$7.3M | −$9.8M | |
| Diluted EPS | −$0.21 | −$0.21 | −$0.19 | −$0.14 | −$0.13 | −$0.18 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $5.6M · Total debt $4.4M · Total assets $8.8M · Shareholders' equity −$3.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 55.92M · Float 54.40M · 97.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 1.63M | 2.92% | 13F | May 15, 2026 |
| Geode Capital Management, LLC | 660.2K | 1.18% | 13F | May 15, 2026 |
| BlackRock, Inc. | 554.0K | 0.99% | 13F | May 13, 2026 |
| Vanguard Fiduciary Trust Co | 307.3K | 0.55% | 13F | May 8, 2026 |
| Blair William & Co/IL | 300.0K | 0.54% | 13F | May 8, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- BioNTech (ADR)
HPV16 mRNA immunotherapy in pivotal HNSCC trial
- Inovio Pharmaceuticals
HPV16/18 DNA and IL-12 immunotherapy for high-risk OPSCC
- Precigen
HPV-associated-cancer immunotherapy in Phase 2 studies
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PDS Biotechnology | $0.2136 | +2.05% | $11.8M | — | — | — | — |
| BioNTech (ADR) | $102.50 | +0.40% | $25.64B | — | — | 8.4 | −60.7% |
| Inovio Pharmaceuticals | $1.29 | 0.00% | $89.1M | — | — | — | — |
| Precigen | $6.97 | +0.50% | $2.48B | — | 13.2 | 28.9 | +6,322.7% |
| Median | — | 13.2 | 18.7 | +3,131.0% |